PL3394083T3 - Pochodne n-[5-[(3,4-dimetoksyfenylo)metylo]-1,3,4-tiadiazol-2-ilo]- 2-metoksybenzenoacetamidu i pokrewne związki jako aktywatory cftr do leczenia zaparcia lub cholestazy - Google Patents
Pochodne n-[5-[(3,4-dimetoksyfenylo)metylo]-1,3,4-tiadiazol-2-ilo]- 2-metoksybenzenoacetamidu i pokrewne związki jako aktywatory cftr do leczenia zaparcia lub cholestazyInfo
- Publication number
- PL3394083T3 PL3394083T3 PL16880156T PL16880156T PL3394083T3 PL 3394083 T3 PL3394083 T3 PL 3394083T3 PL 16880156 T PL16880156 T PL 16880156T PL 16880156 T PL16880156 T PL 16880156T PL 3394083 T3 PL3394083 T3 PL 3394083T3
- Authority
- PL
- Poland
- Prior art keywords
- cholestasis
- thiadiazol
- dimethoxyphenyl
- methoxy
- methyl
- Prior art date
Links
- 206010008635 Cholestasis Diseases 0.000 title 1
- 206010010774 Constipation Diseases 0.000 title 1
- 239000012190 activator Substances 0.000 title 1
- 230000007870 cholestasis Effects 0.000 title 1
- 231100000359 cholestasis Toxicity 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- IKCKBJMUSGLXLU-UHFFFAOYSA-N n-[5-[(3,4-dimethoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]-2-(2-methoxyphenyl)acetamide Chemical class COC1=CC=CC=C1CC(=O)NC(S1)=NN=C1CC1=CC=C(OC)C(OC)=C1 IKCKBJMUSGLXLU-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Prostheses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562387591P | 2015-12-24 | 2015-12-24 | |
| EP16880156.1A EP3394083B9 (en) | 2015-12-24 | 2016-12-23 | N-[5-[(3,4-dimethoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]-2-methoxy-benzeneacetamide derivatives and related compounds as cftr activators for treating constipation or cholestasis |
| PCT/US2016/068561 WO2017112947A1 (en) | 2015-12-24 | 2016-12-23 | Cftr regulators and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3394083T3 true PL3394083T3 (pl) | 2022-01-17 |
Family
ID=59091233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16880156T PL3394083T3 (pl) | 2015-12-24 | 2016-12-23 | Pochodne n-[5-[(3,4-dimetoksyfenylo)metylo]-1,3,4-tiadiazol-2-ilo]- 2-metoksybenzenoacetamidu i pokrewne związki jako aktywatory cftr do leczenia zaparcia lub cholestazy |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190031630A1 (https=) |
| EP (1) | EP3394083B9 (https=) |
| JP (1) | JP6894902B2 (https=) |
| KR (1) | KR102723194B1 (https=) |
| CN (1) | CN108699107B (https=) |
| AU (2) | AU2016377782B2 (https=) |
| CL (1) | CL2018001714A1 (https=) |
| CO (1) | CO2018007239A2 (https=) |
| ES (1) | ES2901002T3 (https=) |
| IL (2) | IL299924B2 (https=) |
| PL (1) | PL3394083T3 (https=) |
| PT (1) | PT3394083T (https=) |
| RU (1) | RU2742934C2 (https=) |
| WO (1) | WO2017112947A1 (https=) |
| ZA (1) | ZA201804228B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383072B (es) | 2015-12-24 | 2025-03-13 | Univ California | Reguladores del cftr y métodos para su uso |
| IT201700085714A1 (it) * | 2017-07-26 | 2019-01-26 | Luigi Maiuri | Approccio terapeutico per il trattamento e/o prevenzione di condizioni di sensibilità al glutine. |
| JP2020531511A (ja) * | 2017-08-24 | 2020-11-05 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | 眼球用医薬組成物 |
| FR3096890B1 (fr) * | 2019-06-07 | 2021-05-14 | H4 Orphan Pharma | Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique. |
| US20220071549A1 (en) * | 2020-09-08 | 2022-03-10 | The Regents Of The University Of California | Apparatus, systems and methods of use for ocular surface potential difference measurement |
| AU2021363703A1 (en) | 2020-10-23 | 2023-06-22 | S2Cbio Inc. | Cftr modulator compounds, compositions, and uses thereof |
| CN113527225B (zh) * | 2021-07-15 | 2022-11-18 | 南昌大学 | 一种丙烯酰噻二唑衍生物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010042298A (ko) | 1998-03-31 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 인자 Ｘａ 및 트롬빈과 같은 세린 프로테아제억제제로서의 퀴녹살리논 |
| AU2003277162C1 (en) * | 2002-09-30 | 2009-12-24 | The Regents Of The University Of California | Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof |
| MXPA06008606A (es) * | 2004-01-30 | 2007-04-13 | Vertex Pharma | Moduladores de transportadores con casete de union a atp. |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US20090105240A1 (en) * | 2007-10-17 | 2009-04-23 | Tomas Mustelin | Methods for treating leukemia and myelodysplastic syndrome, and methods for identifying agents for treating same |
| EP2247580B1 (en) | 2008-03-05 | 2015-07-08 | Merck Patent GmbH | Quinoxalinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes |
| US8314239B2 (en) | 2008-10-23 | 2012-11-20 | Vertex Pharmaceutical Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2010073011A2 (en) * | 2008-12-23 | 2010-07-01 | Betagenon Ab | Compounds useful as medicaments |
| WO2012092471A2 (en) * | 2010-12-29 | 2012-07-05 | Development Center For Biotechnology | Novel tubulin inhibitors and methods of using the same |
| CA2942386A1 (en) * | 2014-03-13 | 2015-09-17 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for increasing cftr activity |
| CA2952862A1 (en) * | 2014-06-19 | 2015-12-23 | Proteostasis Therapeutics, Inc. | Compounds, compositions and methods of increasing cftr activity |
-
2016
- 2016-12-23 JP JP2018533127A patent/JP6894902B2/ja active Active
- 2016-12-23 AU AU2016377782A patent/AU2016377782B2/en active Active
- 2016-12-23 RU RU2018126959A patent/RU2742934C2/ru active
- 2016-12-23 KR KR1020187021185A patent/KR102723194B1/ko active Active
- 2016-12-23 WO PCT/US2016/068561 patent/WO2017112947A1/en not_active Ceased
- 2016-12-23 PL PL16880156T patent/PL3394083T3/pl unknown
- 2016-12-23 CN CN201680082474.2A patent/CN108699107B/zh active Active
- 2016-12-23 EP EP16880156.1A patent/EP3394083B9/en active Active
- 2016-12-23 PT PT168801561T patent/PT3394083T/pt unknown
- 2016-12-23 ES ES16880156T patent/ES2901002T3/es active Active
- 2016-12-23 IL IL299924A patent/IL299924B2/en unknown
- 2016-12-23 US US16/016,300 patent/US20190031630A1/en not_active Abandoned
-
2018
- 2018-06-21 CL CL2018001714A patent/CL2018001714A1/es unknown
- 2018-06-21 IL IL260210A patent/IL260210B2/en unknown
- 2018-06-22 ZA ZA2018/04228A patent/ZA201804228B/en unknown
- 2018-07-11 CO CONC2018/0007239A patent/CO2018007239A2/es unknown
-
2019
- 2019-10-28 US US16/666,278 patent/US11192869B2/en active Active
-
2021
- 2021-10-26 AU AU2021257948A patent/AU2021257948B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3394083T3 (pl) | Pochodne n-[5-[(3,4-dimetoksyfenylo)metylo]-1,3,4-tiadiazol-2-ilo]- 2-metoksybenzenoacetamidu i pokrewne związki jako aktywatory cftr do leczenia zaparcia lub cholestazy | |
| IL276333B (en) | Cyclic sulfamoylarylamide history and their use as drugs to treat hepatitis b | |
| IL245882A0 (en) | A process for the preparation of n-[(3-aminooxan-3-yl)methyl]-2-(1,1-dioxo-5,3-dihydro-4,1-benzothiazen-4-yl)-6-methylquinazoline- 4-Amin | |
| IL254044A0 (en) | Thiadiazole compounds and 1,3,4-oxadiazole modified in position 3 for use as immunomodulators | |
| ZA201706531B (en) | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators | |
| IL254040A0 (en) | Thiadiazole and 1,2,4-oxadiazole compounds for use as immunomodulators | |
| IL254046A0 (en) | Thiadiazole and 1,3,4-oxadiazole compounds for use as immunomodulators | |
| ZA201703905B (en) | 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis | |
| IL260515B1 (en) | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone | |
| SG11201704628VA (en) | Macrocyclic compounds as irak1/4 inhibitors and uses thereof | |
| IL265298B (en) | History of 5-[2-(pyridin-2-ylamino)-3,1-thiazol-5-yl]-3,2,dihydro-1 h -isoindol-1-one and their use as dual inhibitors of phosphatidylinositol 3-kinase delta and gamma | |
| IL259617B (en) | Methods for the preparation of 3,1-benzodioxole heterocyclic compounds | |
| ZA202003981B (en) | Process for the preparation of 2-(5-methoxyisochroman-1 -yl)-4,5-dihydro-1 h-imidazole and the hydrogensulfate salt thereof | |
| LT3212644T (lt) | 2-(1,2,4-triazol-3-ilsulfanil)-n-1,3,4-tiadiazol-2-ilacetamido dariniai, kurie yra naudotini diabeto gydymui | |
| ZA201603729B (en) | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine | |
| TH1501007248A (th) | (+)-5-(3,4ไดฟลูออโรฟีนิล)-5-[(3-เมธิล-2-ออกโซไพริดิน-1(2h)-อิล)เมธิล] อิมิดาโซลิดีน-2,4-ไดโอน และ ยาที่ประกอบด้วยสิ่งเดียวกันนั้น | |
| FI20150289A (fi) | Menetelmä tuhkan määrän, koostumuksen ja ominaisuuksien hallitsemiseksi leijupetiprosessissa |